Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Vaccinations

Vaccinations

What is the Immune System?

What is the Immune System?

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Humoral Immune Responses

Humoral Immune Responses

Health Information Technology and Healthcare Information System

Health Information Technology and Healthcare Information System

Health Information Technology (HIT)
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Engineering T cells with a novel PD-L1-specific TCR targeting immune and cancer cells.

Signal transduction and targeted therapy·2026

Same author

Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond.

Signal transduction and targeted therapy·2026

Same author

Immune reconstitution in patients with myelofibrosis conditioned with a non-myeloablative regimen prior to allogeneic stem cell transplantation.

Bone marrow transplantation·2026

Same author

Rationale for multi-epitope TGFβ vaccination in pancreatic cancer: evidence from immunologic and clinical correlates.

Signal transduction and targeted therapy·2026

Same author

Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma.

Nature communications·2025

Same author

β-adrenergic signaling blockade attenuates metastasis through activation of cytotoxic CD4 T cells.

Nature communications·2025

Same journal

The interaction between inflammation and estrogen in adenomyosis : from molecular mechanisms to therapeutic strategies.

Seminars in immunopathology·2026

Same journal

The complex of gut microbial metabolites and sex hormones in Alzheimer's disease.

Seminars in immunopathology·2026

Same journal

Endometrial pathophysiology and pregnancy: from mechanism to intervention.

Seminars in immunopathology·2026

Same journal

Advances in understanding the dual roles of testicular immune responses: From immune privilege to inflammation.

Seminars in immunopathology·2026

Same journal

Climate change-associated heat extremes and immune dysregulation: emerging links with autoimmunity, allergy, and infectious diseases.

Seminars in immunopathology·2026

Same journal

The cancer-microbiome axis: Mechanisms and emerging therapeutic strategies.

Seminars in immunopathology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Feb 8, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

The T-win® technology: immune-modulating vaccines.

Mads Hald Andersen^1,2,3

¹Center for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730, Herlev, Denmark. mads.hald.andersen@regionh.dk.

Seminars in Immunopathology

|July 4, 2018

Summary

This summary is machine-generated.

T-win® technology activates anti-regulatory T cells (anti-Tregs) to target cancer cells by vaccinating with long peptide epitopes. This approach safely modifies the tumor microenvironment, enhancing anti-tumor immune responses with minimal toxicity.

Keywords:

Anti-Tregs Arginase IDO Immune-modulating vaccines PD-L1 T-win technology

More Related Videos

Immunization of Adult Zebrafish for the Preclinical Screening of DNA-based Vaccines

Immunization of Adult Zebrafish for the Preclinical Screening of DNA-based Vaccines

Published on: October 30, 2018

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

Related Experiment Videos

Last Updated: Feb 8, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

Immunization of Adult Zebrafish for the Preclinical Screening of DNA-based Vaccines

Immunization of Adult Zebrafish for the Preclinical Screening of DNA-based Vaccines

Published on: October 30, 2018

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

Area of Science:

Immunology
Oncology
Vaccine Technology

Background:

Regulatory T cells (Tregs) suppress anti-tumor immunity.
Tumor microenvironments often exhibit immune-suppressive properties.
Targeting immune checkpoints like IDO and PD-L1 is a key strategy in cancer therapy.

Purpose of the Study:

To introduce T-win® technology, an innovative approach to activate endogenous anti-regulatory T cells (anti-Tregs).
To investigate the potential of T-win® to target regulatory and malignant cells within the tumor microenvironment.
To explore the modification of the tumor immune environment from regulatory to pro-inflammatory to enhance anti-tumor responses.

Main Methods:

Therapeutic vaccination using long peptide epitopes derived from antigens recognized by anti-Tregs (e.g., IDO, PD-L1).
Activation of both CD4 and CD8 anti-Tregs.
Evaluation of safety and toxicity in clinical trials.

Main Results:

T-win® technology targets genetically stable cells with regular human leukocyte antigen expression.
The approach attracts pro-inflammatory cells, altering immune inhibitory pathways and potentially overcoming tolerance to tumor antigens.
Vaccinations against IDO or PD-L1 to potentiate anti-Tregs have demonstrated safety with minimal toxicity in clinical trials.

Conclusions:

T-win® technology offers a novel strategy to reprogram the tumor microenvironment towards a pro-inflammatory state.
This immune modulation potentiates effective anti-tumor T cell responses by reverting regulatory immune cells into effector cells.
The T-win® approach, targeting indoleamine 2,3-dioxygenase (IDO) or programmed death ligand 1 (PD-L1), shows promise as a safe and effective cancer immunotherapy.